The Magazine for Sleep Professionals
Tuesday, September 15, 2026
ProSomnus Sleep Technologies (“ProSomnus”) has announced a significant victory in its intellectual property enforcement action, reinforcing the Company’s commitment to protecting the innovations, technologies, and proprietary assets that support advances in sleep medicine. The United States District Court for the Southern District of Florida adopted in full the Magistrate Judge’s Report […]
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
ProSomnus Sleep Technologies announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The RPMO2 OSA Device is the first theragnostic device for sleep medicine, incorporating both precision […]
ProSomnus Sleep Technologies announced a strategic investment from Catalio Capital Management, L.P. to accelerate the global expansion of its technology-enabled sleep health platform. Under the agreement, Catalio, a premier healthcare-focused investment firm, has committed up to $38 million to advance development of next-generation remote patient monitoring (RPM) and proprietary sleep […]
ProSomnus Sleep Technologies announced its inclusion on the prestigious Inc. 5000 list of fastest growing private companies in the USA. This is the fourth year that ProSomnus has earned a spot on the Inc. 5000 list. Persistent and robust organic demand for ProSomnus’s sleep apnea devices, as opposed to price […]
ProSomnus Sleep Technologies announced significant progress on strategic programs. The key feature is the successful FDA registration of the company’s HWO2 buccal mucosal wellness oximeter. The ProSomnus HWO2 Device enables patients to monitor their nightly health and wellness during sleep, specifically, blood oxygen saturation, pulse rate and overall use time, […]
ProSomnus Sleep Technologies announces EVO Guided. EVO Guided is a new precision, custom oral device for the treatment of Obstructive Sleep Apnea (“OSA”). FDA cleared, patented and covered by most medical insurances, EVO Guided is the first oral device bioengineered to dilate the oropharynx and the velopharynx for optimal therapeutic […]
ProSomnus Sleep Technologies announced record revenues for the quarter that ended June 30, 2024, as it formally emerged from reorganization on August 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% […]
ProSomnus, Inc. announced it has initiated a voluntary restructuring process under Chapter 11 of the U.S. Bankruptcy Code to reorganize and strengthen its capital structure going forward, improve financial flexibility and better position the company for long-term success. In connection with this process, the Company has secured the support of […]
ProSomnus, Inc. has announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are also participating in the financing. A description of the terms of the offering can […]
